Zenas BioPharma (NASDAQ:ZBIO) Director Buys $109,657.60 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Patricia Allen purchased 4,160 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was acquired at an average price of $26.36 per share, for a total transaction of $109,657.60. Following the acquisition, the director directly owned 19,860 shares of the company’s stock, valued at $523,509.60. This trade represents a 26.50% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Zenas BioPharma Trading Up 1.1%

ZBIO traded up $0.29 during trading on Friday, hitting $26.40. 1,084,522 shares of the company’s stock were exchanged, compared to its average volume of 1,195,034. Zenas BioPharma, Inc. has a 1 year low of $6.11 and a 1 year high of $44.60. The stock has a 50 day moving average price of $27.82 and a 200 day moving average price of $25.51. The firm has a market cap of $1.42 billion, a P/E ratio of -3.73 and a beta of -1.50. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in Zenas BioPharma during the 4th quarter worth $38,000. Quarry LP lifted its position in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Zenas BioPharma in the third quarter worth about $30,000. CWM LLC increased its holdings in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after buying an additional 709 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Zenas BioPharma during the fourth quarter valued at approximately $95,000.

Wall Street Analyst Weigh In

ZBIO has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $44.00 price objective on shares of Zenas BioPharma in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Citigroup boosted their price target on Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Morgan Stanley downgraded shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Finally, Evercore started coverage on shares of Zenas BioPharma in a research note on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.